Michael McGuire is a seasoned pharmaceutical industry executive with extensive expertise in P&L management, strategic planning, marketing, and new product development. Throughout his career, he has successfully led commercialization efforts for billion-dollar brands, built alliances with government agencies, enhanced consumer awareness, and driven major cost efficiencies.
Prior to joining Citius Pharmaceuticals, he served as Senior Vice President of Commercial, Government Affairs, and Customer Engagement at Melinta Therapeutics where he led government relations initiatives with Congress, CMS, and BARDA to advance the DISARM Act, aiming to reshape anti-infective reimbursement policies. He integrated three commercial organizations (Melinta, Cempra, and The Medicines Company), launched two new anti-infective therapies, and helped secure a $125 million capital investment through strategic investor engagement.
Previously, at The Medicines Company, Michael served as Senior Vice President, Global Infectious Disease, managing global commercial operations for the anti-infective portfolio and leading the successful launch of Orbactiv™ in a competitive market. He played a key role in the acquisition of Rempex Pharmaceuticals and contributed to the company’s eventual acquisition by Melinta.
Earlier in his career at Roche Laboratories, Michael led the Tamiflu franchise to become Roche’s first billion-dollar U.S. product. He developed an award-winning direct-to-consumer campaign, designed the North American pandemic plan, and spearheaded Roche’s response during the 2009–2010 swine flu outbreak.
Michael holds an MBA in Marketing from Montclair State College and a BS in Biology from Mary Washington College.